CHENGDU EASTON BIOPHARMACEUTICALS CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 57.24 CNY | -1.34% |
|
-1.62% | -10.25% |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 5,715 | 5,572 | 7,306 | 7,659 | 6,811 | - | - |
| Enterprise Value (EV) 1 | 5,715 | 5,572 | 7,306 | 7,659 | 6,811 | 6,811 | 6,811 |
| P/E ratio | 26.7 x | 23.9 x | 29.7 x | 33.9 x | 23.6 x | 19 x | 15.1 x |
| Yield | - | - | - | 0.91% | 1.33% | 1.59% | - |
| Capitalization / Revenue | - | 5.45 x | 6.24 x | 6.86 x | 4.68 x | 3.85 x | 3 x |
| EV / Revenue | - | 5.45 x | 6.24 x | 6.86 x | 4.68 x | 3.85 x | 3 x |
| EV / EBITDA | - | 20.1 x | 22.9 x | 24.2 x | 13.4 x | 13 x | 9.46 x |
| EV / FCF | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - |
| Price to Book | - | 2.43 x | 2.99 x | 2.94 x | 2.43 x | 2.19 x | 1.98 x |
| Nbr of stocks (in thousands) | 120,090 | 120,090 | 120,090 | 120,090 | 118,999 | - | - |
| Reference price 2 | 47.59 | 46.40 | 60.84 | 63.78 | 57.24 | 57.24 | 57.24 |
| Announcement Date | 21-03-29 | 22-02-25 | 23-02-27 | 24-02-23 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 1,023 | 1,171 | 1,117 | 1,454 | 1,771 | 2,272 |
| EBITDA 1 | - | 276.8 | 319 | 316.5 | 508 | 524.5 | 720 |
| EBIT 1 | - | 244.2 | 260.6 | 243.9 | 306 | 389.3 | 484 |
| Operating Margin | - | 23.87% | 22.27% | 21.84% | 21.05% | 21.99% | 21.3% |
| Earnings before Tax (EBT) 1 | - | 246.9 | 262 | 243.8 | 308 | 391 | 486 |
| Net income 1 | 178.2 | 232.4 | 246.5 | 226.3 | 291.3 | 361.7 | 457 |
| Net margin | - | 22.72% | 21.06% | 20.27% | 20.04% | 20.42% | 20.11% |
| EPS 2 | 1.780 | 1.940 | 2.050 | 1.880 | 2.427 | 3.010 | 3.800 |
| Free Cash Flow | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | 0.5800 | 0.7600 | 0.9100 | - |
| Announcement Date | 21-03-29 | 22-02-25 | 23-02-27 | 24-02-23 | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | 10.6% | 10.5% | 8.98% | 10.4% | 11.7% | 13.2% |
| ROA (Net income/ Total Assets) | - | - | - | 7.12% | 8.1% | 8.9% | - |
| Assets 1 | - | - | - | 3,180 | 3,597 | 4,064 | - |
| Book Value Per Share 2 | - | 19.10 | 20.40 | 21.70 | 23.50 | 26.20 | 28.80 |
| Cash Flow per Share 2 | - | 1.230 | 1.270 | 2.290 | 4.880 | 4.620 | 5.950 |
| Capex 1 | - | 256 | 339 | 175 | 700 | 80 | - |
| Capex / Sales | - | 25.05% | 28.96% | 15.67% | 48.14% | 4.52% | - |
| Announcement Date | 21-03-29 | 22-02-25 | 23-02-27 | 24-02-23 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
57.24
Average target price
-
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -10.25% | 956M | |
| +34.35% | 693B | |
| +29.39% | 584B | |
| -3.49% | 372B | |
| +20.15% | 332B | |
| +6.19% | 294B | |
| +14.11% | 239B | |
| -3.03% | 211B | |
| +10.02% | 210B | |
| +9.21% | 168B |
- Stock Market
- Equities
- 688513 Stock
- Financials Chengdu Easton Biopharmaceuticals Co., Ltd.
